Metal Complexes in Target‐Specific Anticancer Therapy: Recent Trends and Challenges

G Shumi, T Desalegn, TB Demissie… - Journal of …, 2022 - Wiley Online Library
Cancer is characterized by abnormal cell differentiation in or on the part of the body. The
most commonly used chemotherapeutic drugs are developed to target rapidly dividing cells …

Discovery of thirteen cobalt (II) and copper (II) salicylaldehyde Schiff base complexes that induce apoptosis and autophagy in human lung adenocarcinoma A549/DDP …

YT Chen, SN Zhang, ZF Wang, QM Wei… - Dalton Transactions, 2022 - pubs.rsc.org
In this study, 13 transition metal complexes, namely,[Cu (L1H)(H2O) 2]·(H2O)· NO3 (1),[Cu
(LnH2) 2]·(NO3)·(H2O) 2 (2, n= 2; 3, n= 3; 4, n= 4; 5, n= 5),[Co (LnH) 2] 2·(H2O) 0.5 (6, n= 2; …

Metal complexes bearing EGFR‐inhibiting ligands as promising anticancer agents

X Ma, Z Wang, Y Li, Y Wang… - Medicinal Research …, 2024 - Wiley Online Library
Overexpression of the epidermal growth factor receptor (EGFR, erbB1) has been observed
in a wide range of solid tumors and has frequently been associated with poor prognosis. As …

Cobalt (III) complexes for light-activated delivery of acetylacetonate-BODIPY, cellular Imaging, and Photodynamic Therapy

A Jana, P Kundu, S Paul, P Kondaiah… - Inorganic …, 2022 - ACS Publications
Cobalt (III) complexes [Co (TPA)(L1)](ClO4) 2 (1),[Co (4-COOH-TPA)(L1)](ClO4) 2 (2),[Co
(TPA)(L2)] Cl2 (3), and [Co (4-COOH-TPA)(L2)] Cl2 (4) having acetylacetonate-linked boron …

Cobalt (III) dibromo-BODIPY-8-hydroxyquinolinate for mitochondria-targeted red light photodynamic therapy

A Jana, S Sahoo, S Paul, S Sahoo, C Jayabaskaran… - Polyhedron, 2023 - Elsevier
The photophysical properties of boron-dipyrromethene (BODIPY) dyes have made them
suitable for cellular imaging and photodynamic therapy (PDT). The efficacy of these dyes …

Development of a cobalt (III)-based ponatinib prodrug system

M Mathuber, M Gutmann, M La Franca… - Inorganic Chemistry …, 2021 - pubs.rsc.org
Receptor tyrosine kinase inhibitors have become a central part of modern targeted cancer
therapy. However, their curative potential is distinctly limited by both rapid resistance …

Photodynamic Therapy with Targeted Release of Boron-Dipyrromethene Dye from Cobalt (III) Prodrugs in Red Light

A Jana, S Sahoo, S Paul, S Sahoo… - Inorganic …, 2024 - ACS Publications
Boron-dipyrromethene (BODIPY) dyes are promising photosensitizers for cellular imaging
and photodynamic therapy (PDT) owing to their excellent photophysical properties and the …

Metal-tyrosine kinase inhibitors: targeted metal-drug conjugates

DF Beirne, M Dalla Via, T Velasco-Torrijos… - Coordination Chemistry …, 2022 - Elsevier
Tyrosine Kinases are enzymes that catalyse the phosphorylation of the tyrosine residues of
their substrates and activate downstream pathways involved in cellular proliferation. Their …

[HTML][HTML] In vitro biodistribution studies on clinically approved FGFR inhibitors ponatinib, nintedanib, erlotinib and the investigational inhibitor KP2692

O Dömötör, M Mathuber, CR Kowol - European Journal of Pharmaceutical …, 2024 - Elsevier
Binding towards human serum albumin (HSA) and α1-acid glycoprotein (AGP) of three
approved fibroblast growth factor receptor (FGFR) inhibitors ponatinib (PON), nintedanib …

[HTML][HTML] Cobalt (III)-py2en systems as potential carriers of β-ketoester-based ligands

MV Palmeira-Mello, AB Caballero… - Journal of Inorganic …, 2023 - Elsevier
Two cobalt (III) complexes containing different β-ketoesters, namely [Co III (L1)(py 2 en)](ClO
4) 2· H 2 O (1) and [Co III (L2)(py 2 en)](ClO 4) 2 (2)(py 2 en= N, N′-bis (pyridin-2-ylmethyl) …